The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2052698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716897180811264 |
|---|---|
| author | Yongrong Zhang Ashley Saint Fleur Hanping Feng |
| author_facet | Yongrong Zhang Ashley Saint Fleur Hanping Feng |
| author_sort | Yongrong Zhang |
| collection | DOAJ |
| description | Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against C. difficile colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field. |
| format | Article |
| id | doaj-art-808a5b0afefb4dea96027a64bf4abf1d |
| institution | DOAJ |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-808a5b0afefb4dea96027a64bf4abf1d2025-08-20T03:12:50ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2052698The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiotaYongrong Zhang0Ashley Saint Fleur1Hanping Feng2Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, United StatesDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, United StatesDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, United StatesClostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against C. difficile colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field.https://www.tandfonline.com/doi/10.1080/19490976.2022.2052698Clostridioides difficilemicrobiotabiotherapeuticsdysbiosisreconstitution |
| spellingShingle | Yongrong Zhang Ashley Saint Fleur Hanping Feng The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota Gut Microbes Clostridioides difficile microbiota biotherapeutics dysbiosis reconstitution |
| title | The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota |
| title_full | The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota |
| title_fullStr | The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota |
| title_full_unstemmed | The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota |
| title_short | The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota |
| title_sort | development of live biotherapeutics against clostridioides difficile infection towards reconstituting gut microbiota |
| topic | Clostridioides difficile microbiota biotherapeutics dysbiosis reconstitution |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2052698 |
| work_keys_str_mv | AT yongrongzhang thedevelopmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota AT ashleysaintfleur thedevelopmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota AT hanpingfeng thedevelopmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota AT yongrongzhang developmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota AT ashleysaintfleur developmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota AT hanpingfeng developmentoflivebiotherapeuticsagainstclostridioidesdifficileinfectiontowardsreconstitutinggutmicrobiota |